"With MRI-targeted transperineal biopsy and PSMA PET scanning, Australia has led the world in prostate cancer diagnosis.
Now we’re leading in treatment, using focal therapy for localised medium-risk prostate cancer in trials and clinical registries, aiming to keep treatment side effects to a bare minimum."
A/Prof Jeremy Grummet
Dr Jeremy Grummet
> Urological Surgeon at Cabrini, Epworth, St Vincent’s Private Werribee and Bairnsdale Hospitals
> Director of Urology, Alfred Health
> Clinical Associate Professor
Department of Surgery
Monash University
> Former EAU Prostate Cancer Guidelines Panel Member
> Co-Principal Investigator of the LIBERATE focal brachytherapy clinical registry
Prostate / Kidney /
Bladder / Genitalia
> Focal therapy for prostate cancer
> Robotic prostatectomy
> Advanced diagnostics for prostate cancer
• MRI-targeted prostate biopsy
• Transperineal prostate biopsy
• PSMA PET scanning
> Active surveillance of low risk prostate cancer
> Treatment of high risk localised prostate cancer
> General urology
> Focal therapy for prostate cancer
> Prostate MRI
> Transperineal biopsy
> Transrectal biopsy sepsis risk
> Peer-reviewed publications
> Scientific conference presentations
> Master of Surgery thesis
> Television appearances
> Radio interviews
> Magazine articles
> Invited speaker conference presentations
> Community presentations
> What is a urologist?
> What to bring to an appointment
> Telehealth service
> Useful links
> What is a PSA?
> What is the Gleason score?
> Near zero sepsis risk of transperineal biopsy
> Multiparametric MRI - Changing the Face of Prostate Cancer Diagnosis
> A/Prof Grummet in Focal therapy webinars
> A/Prof Grummet explains prostate biopsy - Andrology Australia Youtube video
> Da Vinci robotic technology used by A/Prof Grummet for robotic prostatectomy
